effect of devdaruvadi churna,shunthyadi kwatha and saindhwadi tail matra basti in AMAVATA (RHEUMATOID ARTHRITIS)

A clinical study to evaluate the efficacy of regime (Devadaruvadi churna and Shunthyadi Kwatha with Saindhwadi taila matra Basti) in the management of Amavata W.S.R. Rhuematoid Arthritis

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/02/017640

Enrollment

Registered

2019-02-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M048- Other autoinflammatory syndromes

Interventions

Intervention1: Devadarvadi churna -5gm bd Shunthayadi Kwatha -40ml bd Saindhavadi Taila Matra Basti for 10 days: Devadarvadi Churna 5mg per oral with luke warm warter bd and Shunthayadi kwatha 40ml pe

Eligibility

Inclusion criteria

Inclusion criteria: Patients fulfilling American College of Rheumatology (ACR) criteria,1987.

Exclusion criteria

Exclusion criteria: Patients having severe crippling deformity. Patients with other systemic diseases like cardiac diseases ,TB,DM ect. Any other serious medically and surgically ill patients

Design outcomes

Primary

Measure	Time frame
To assess the effect of therapy,objectively all sign and symptoms were given scoring depending upon their severity. complete remission-100% maximum improvement-75-99% moderate improvement-50-74% mild improvement-25-49% no improvement-0-24% Timepoint: Duration of study -45 days The assessment of the patients will be done for three times at the interval of 15 days Follow up of the patients will be done 30 days after completion of trial.	—

Measure

Time frame

To assess the effect of therapy,objectively all sign and symptoms were given scoring depending upon their severity. complete remission-100% maximum improvement-75-99% moderate improvement-50-74% mild improvement-25-49% no improvement-0-24% Timepoint: Duration of study -45 days The assessment of the patients will be done for three times at the interval of 15 days Follow up of the patients will be done 30 days after completion of trial.

—

Secondary

Measure	Time frame
Relief in all sign and symptomes of AmavataTimepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Jaya Saklani Kala

Rishikul Campus

jk1ayush@gmail.com9927249201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026